BioGenCell has developed a long-term road map for the next five years and beyond.
Our goal is to reach commercialization of the first product based on FDA’s and EMA’s expedited programs while developing a pipeline of additional products based on our technology platform.
A phase I/II multi-centered randomized-controlled-study in 40 patients was approved in Israel and in Belgium. This will be followed by a pivotal phase III study.
A market leading position in bringing stem cell treatments to patients in every clinic will be achieved due to the technology’s superior safety and scalability. BioGenCell will add value and open a competitive gap by creating a revenue stream based on FDA’s and EMA’s expedited programs. By the end of the clinical trials, the company will have developed strategic partnerships and distribution channels.
